ADRA2A

Across TCGA pan-cancer cohorts, ADRA2A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ADRA2A data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ADRA2A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADRA2A expression acts as an unfavorable survival marker.

BRCA, ACC, and SKCM are the cancer types where ADRA2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.294	0.903	<.001	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	OS	Median	III,IV	0.289	0.840	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ADRA2A–BRCA (DFS)

Open the BRCA breakdown →